Paul Welsh1, Dorien M Kimenai2, Riccardo E Marioni3, Caroline Hayward4, Archie Campbell3, David Porteous3, Nicholas L Mills2,5, Stephen O'Rahilly6,7, Naveed Sattar1. 1. School of Cardiovascular & Metabolic Health, University of Glasgow, Glasgow, UK. 2. BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK. 3. Institute of Genetics and Cancer (IGC), University of Edinburgh, Edinburgh, UK. 4. MRC Human Genetics Unit (HGU), University of Edinburgh, Edinburgh, UK. 5. Usher Institute, University of Edinburgh, Edinburgh, UK. 6. MRC Metabolic Diseases Unit, Wellcome - MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK. 7. NIHR Cambridge Biomedical Research Centre, Cambridge, UK.
Abstract
OBJECTIVES: Growth differentiation factor (GDF)-15 is attracting interest as a biomarker in several areas of medicine. We aimed to evaluate the reference range for GDF-15 in a general population, and to explore demographics, classical cardiovascular disease risk factors, and other cardiac biomarkers associated with GDF-15. METHODS: GDF-15 was measured in serum from 19,462 individuals in the Generation Scotland Scottish Family Health Study. Associations of cardiometabolic risk factors with GDF-15 were tested using adjusted linear regression. Among 18,507 participants with no heart disease, heart failure, or stroke, and not pregnant, reference ranges (median and 97.5th centiles) were derived by decade age bands and sex. RESULTS: Among males in the reference range population, median (97.5th centile) GDF-15 concentration at age <30 years was 537 (1,135) pg/mL, rising to 931 (2,492) pg/mL at 50-59 years, and 2,152 (5,972) pg/mL at ≥80 years. In females, median GDF-15 at age <30 years was 628 (2,195) pg/mL, 881 (2,323) pg/mL at 50-59 years, and 1847 (6,830) pg/mL at ≥80 years. Among those known to be pregnant, median GDF-15 was 19,311 pg/mL. After adjustment, GDF-15 was higher in participants with adverse cardiovascular risk factors, including current smoking (+26.1%), those with previous heart disease (+12.7%), stroke (+17.1%), heart failure (+25.3%), and particularly diabetes (+60.2%). GDF-15 had positive associations with cardiac biomarkers cardiac troponin I, cardiac troponin T, and N-terminal pro B-type natriuretic peptide (NT-proBNP). CONCLUSIONS: These data define reference ranges for GDF-15 for comparison in future studies, and identify potentially confounding risk factors and mediators to be considered in interpreting GDF-15 concentrations.
OBJECTIVES: Growth differentiation factor (GDF)-15 is attracting interest as a biomarker in several areas of medicine. We aimed to evaluate the reference range for GDF-15 in a general population, and to explore demographics, classical cardiovascular disease risk factors, and other cardiac biomarkers associated with GDF-15. METHODS: GDF-15 was measured in serum from 19,462 individuals in the Generation Scotland Scottish Family Health Study. Associations of cardiometabolic risk factors with GDF-15 were tested using adjusted linear regression. Among 18,507 participants with no heart disease, heart failure, or stroke, and not pregnant, reference ranges (median and 97.5th centiles) were derived by decade age bands and sex. RESULTS: Among males in the reference range population, median (97.5th centile) GDF-15 concentration at age <30 years was 537 (1,135) pg/mL, rising to 931 (2,492) pg/mL at 50-59 years, and 2,152 (5,972) pg/mL at ≥80 years. In females, median GDF-15 at age <30 years was 628 (2,195) pg/mL, 881 (2,323) pg/mL at 50-59 years, and 1847 (6,830) pg/mL at ≥80 years. Among those known to be pregnant, median GDF-15 was 19,311 pg/mL. After adjustment, GDF-15 was higher in participants with adverse cardiovascular risk factors, including current smoking (+26.1%), those with previous heart disease (+12.7%), stroke (+17.1%), heart failure (+25.3%), and particularly diabetes (+60.2%). GDF-15 had positive associations with cardiac biomarkers cardiac troponin I, cardiac troponin T, and N-terminal pro B-type natriuretic peptide (NT-proBNP). CONCLUSIONS: These data define reference ranges for GDF-15 for comparison in future studies, and identify potentially confounding risk factors and mediators to be considered in interpreting GDF-15 concentrations.
Authors: Blair H Smith; Archie Campbell; Pamela Linksted; Bridie Fitzpatrick; Cathy Jackson; Shona M Kerr; Ian J Deary; Donald J Macintyre; Harry Campbell; Mark McGilchrist; Lynne J Hocking; Lucy Wisely; Ian Ford; Robert S Lindsay; Robin Morton; Colin N A Palmer; Anna F Dominiczak; David J Porteous; Andrew D Morris Journal: Int J Epidemiol Date: 2012-07-10 Impact factor: 7.196
Authors: Siobhan M Hamon; Tomás P Griffin; Md Nahidul Islam; Deirdre Wall; Matthew D Griffin; Paula M O'Shea Journal: Clin Chem Lab Med Date: 2019-03-26 Impact factor: 3.694
Authors: A G Moore; D A Brown; W D Fairlie; A R Bauskin; P K Brown; M L Munier; P K Russell; L A Salamonsen; E M Wallace; S N Breit Journal: J Clin Endocrinol Metab Date: 2000-12 Impact factor: 5.958
Authors: Tibor Kempf; Rüdiger Horn-Wichmann; Georg Brabant; Timo Peter; Tim Allhoff; Gunnar Klein; Helmut Drexler; Nina Johnston; Lars Wallentin; Kai C Wollert Journal: Clin Chem Date: 2006-12-21 Impact factor: 8.327
Authors: Maren Carstensen; Christian Herder; Eric J Brunner; Klaus Strassburger; Adam G Tabak; Michael Roden; Daniel R Witte Journal: Eur J Endocrinol Date: 2010-02-18 Impact factor: 6.664
Authors: Blair H Smith; Harry Campbell; Douglas Blackwood; John Connell; Mike Connor; Ian J Deary; Anna F Dominiczak; Bridie Fitzpatrick; Ian Ford; Cathy Jackson; Gillian Haddow; Shona Kerr; Robert Lindsay; Mark McGilchrist; Robin Morton; Graeme Murray; Colin N A Palmer; Jill P Pell; Stuart H Ralston; David St Clair; Frank Sullivan; Graham Watt; Roland Wolf; Alan Wright; David Porteous; Andrew D Morris Journal: BMC Med Genet Date: 2006-10-02 Impact factor: 2.103